A Phase 4 interventional study of Valbenazine and Placebo oral capsule in Tardive Dyskinesia (TD), sponsored by Neurocrine Biosciences. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-04.
Sponsored by Neurocrine Biosciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 4, and was the 9th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2018.
This study's enrollment of 89 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2018, is one of 4 in phase 4, and was the 9th registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Valbenazine or placebo oral capsules administered once daily for 7 weeks.
Drug: Valbenazine · Drug: Placebo oral capsule
Placebo oral capsules administered once daily for 7 weeks.
Drug: Placebo oral capsule
vesicular monoamine transporter 2 (VMAT2) inhibitor
Also known as: Ingrezza, NBI-98854
non-active dosage form
Participants With Withdrawal-Emergent Adverse Events
A withdrawal-emergent adverse event is an adverse event that begins during the Withdrawal Period.
Time frame: 3 weeks
Participants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20)
The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Worsening of symptoms is defined by 5 new symptoms of moderate or severe degree or a worsening of symptoms by 2 points on the PWC-20 scale during Weeks 5 to 7 compared with Week 4. Note: a 2-point worsening from 0 (none) at Week 4 to 2 (moderate) post-Week 4 is counted as a worsening of symptoms.
Time frame: 3 weeks
Absolute Worst Total Score as Measured by the Physician Withdrawal Checklist-20 (PWC-20)
The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Larger values indicate more severe symptoms. Rickels et al (J Clin Psychopharmacol 2008) cites PWC-20 mean scores associated with withdrawal in the range of 15 to 24.
Time frame: 3 weeks
Severity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA)
The mCSSA is an 18-item survey based on symptoms commonly associated with early cocaine abstinence, including depression, fatigue, anhedonia, anxiety, irritability, sleep disturbance, and inability to concentrate. Items are rated on scales of 0 to 7 or 0 to 8, with separate scale descriptions for each item. Larger values indicate more severe symptoms. The scale has been modified to be specific to study drug (valbenazine or placebo) instead of cocaine.
Time frame: 7 weeks
Overall Improvement From Baseline of TD Symptoms as Measured by the Clinical Global Impression-Tardive Dyskinesia-Improvement (CGI-TD-I) Score
The CGI-TD-I scale is a 7-point scale (range; 1=very much improved to 7=very much worse) used to assess overall improvement in TD symptoms since the initiation of study drug dosing.
Time frame: Baseline, Week 4, Week 7
Change in Severity of TD Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Tardive Dyskinesia-Severity (CGI-TD-S) Scale
The CGI-TD-S scale is a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patient) used to assess the overall global severity of TD.
Time frame: Baseline, Week 4, Week 7
| Milestone | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Started | 44 | 45 |
| Entered withdrawal period | 42 | 39 |
| Completed | 40 | 39 |
| Not completed | 4 | 6 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
A withdrawal-emergent adverse event is an adverse event that begins during the Withdrawal Period.
| Participants | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Participants With Withdrawal-Emergent Adverse Events | 9 | 13 |
The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Worsening of symptoms is defined by 5 new symptoms of moderate or severe degree or a worsening of symptoms by 2 points on the PWC-20 scale during Weeks 5 to 7 compared with Week 4. Note: a 2-point worsening from 0 (none) at Week 4 to 2 (moderate) post-Week 4 is counted as a worsening of symptoms.
| Participants | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Participants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20) | 9 | 3 |
The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Larger values indicate more severe symptoms. Rickels et al (J Clin Psychopharmacol 2008) cites PWC-20 mean scores associated with withdrawal in the range of 15 to 24.
| score on a scale | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Mean absolute score at baseline | 4.6 ± 5.0 | 3.9 ± 4.5 |
| Mean absolute score at withdrawal baseline | 3.8 ± 3.7 | 3.1 ± 3.8 |
| Mean absolute worst total score | 5.6 ± 5.3 | 3.3 ± 2.6 |
The mCSSA is an 18-item survey based on symptoms commonly associated with early cocaine abstinence, including depression, fatigue, anhedonia, anxiety, irritability, sleep disturbance, and inability to concentrate. Items are rated on scales of 0 to 7 or 0 to 8, with separate scale descriptions for each item. Larger values indicate more severe symptoms. The scale has been modified to be specific to study drug (valbenazine or placebo) instead of cocaine.
| score on a scale | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Severity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA) | 1.9 ± 4.1 | 0.5 ± 3.2 |
The CGI-TD-I scale is a 7-point scale (range; 1=very much improved to 7=very much worse) used to assess overall improvement in TD symptoms since the initiation of study drug dosing.
| score on a scale | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| End of Week 4 | 3.2 ± 0.8 | 3.4 ± 0.7 |
| End of Week 7 | 3.0 ± 0.7 | 3.0 ± 0.8 |
The CGI-TD-S scale is a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patient) used to assess the overall global severity of TD.
| score on a scale | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| End of Week 4 | -0.3 ± 0.7 | -0.2 ± 0.6 |
| End of Week 5 | -0.3 ± 0.6 | -0.3 ± 0.6 |
| End of Week 6 | -0.4 ± 0.5 | -0.5 ± 0.6 |
| End of Week 7 | -0.4 ± 0.5 | -0.5 ± 0.6 |
Collected over Up to 7 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valbenazine/Placebo | 0/44 (0%) | 1/44 (2.3%) | 12/44 (27.3%) |
| Placebo/Placebo | 0/45 (0%) | 1/45 (2.2%) | 19/45 (42.2%) |
| Event | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| Schizoaffective disorderPsychiatric disorders | 1/44 | 0/45 |
| Psychotic disorderPsychiatric disorders | 0/44 | 1/45 |
| Event | Valbenazine/Placebo | Placebo/Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/44 | 2/45 |
| HeadacheNervous system disorders | 2/44 | 5/45 |
| NauseaGastrointestinal disorders | 1/44 | 4/45 |
| Upper respiratory tract infectionInfections and infestations | 1/44 | 4/45 |
| Salivary hypersecretionGastrointestinal disorders | 2/44 | 0/45 |
| VomitingGastrointestinal disorders | 2/44 | 2/45 |
| DizzinessNervous system disorders | 2/44 | 1/45 |
| SomnolenceNervous system disorders | 2/44 | 1/45 |
| Dry eyeEye disorders | 2/44 | 1/45 |
| FatigueGeneral disorders | 2/44 | 0/45 |
| Age, Continuous(years) | Valbenazine/Placebo | Placebo/Placebo | Total |
|---|---|---|---|
| Mean | 54.7 ± 7.5 | 53.6 ± 9.5 | 54.1 ± 8.5 |
| Sex: Female, Male(Participants) | Valbenazine/Placebo | Placebo/Placebo | Total |
|---|---|---|---|
| Female | 19 | 18 | 37 |
| Male | 25 | 27 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Valbenazine/Placebo | Placebo/Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 17 | 36 |
| Not Hispanic or Latino | 25 | 28 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Valbenazine/Placebo | Placebo/Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 19 | 32 |
| White | 30 | 25 | 55 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Apr 2019, 6 months.
Results were first posted in Jun 2020, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine